Investigational Drug Information for Lapaquistat
✉ Email this page to a colleague
What is the development status for investigational drug Lapaquistat?
Lapaquistat is an investigational drug.
There have been 16 clinical trials for Lapaquistat.
The most recent clinical trial was a Phase 3 trial, which was initiated on October 1st 2005.
The most common disease conditions in clinical trials are Hypercholesterolemia, Dyslipidemias, and Hyperlipoproteinemia Type II. The leading clinical trial sponsors are Takeda and [disabled in preview].
Summary for Lapaquistat
| US Patents | 0 |
| International Patents | 0 |
| US Patent Applications | 107 |
| WIPO Patent Applications | 70 |
| Japanese Patent Applications | 18 |
| Clinical Trial Progress | Phase 3 (2005-10-01) |
| Vendors | 26 |
Recent Clinical Trials for Lapaquistat
| Title | Sponsor | Phase |
|---|---|---|
| Efficacy of Lapaquistat Acetate on Blood Cholesterol Levels in Treating Subjects With Hypercholesterolemia | Takeda | Phase 3 |
| Efficacy of Lapaquistat Acetate Co-Administered With Statins in Subjects With Hypercholesterolemia | Takeda | Phase 3 |
| Efficacy of Lapaquistat Acetate in Subjects With Hypercholesterolemia | Takeda | Phase 2 |
Clinical Trial Summary for Lapaquistat
Top disease conditions for Lapaquistat
Top clinical trial sponsors for Lapaquistat
US Patents for Lapaquistat
| Drugname | Patent Number | Patent Title | Patent Assignee | Estimated Expiration |
|---|---|---|---|---|
| >Drugname | >Patent Number | >Patent Title | >Patent Assignee | >Estimated Expiration |
